Effect of diltiazem on renal clearance and serum concentration of digoxin in patients with cardiac disease. 1985

U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola

The effect of diltiazem on digoxin serum concentration was evaluated in 9 patients who had been treated chronically for heart disease with digoxin, 0.25 mg/day. The indications for digoxin therapy were arrhythmias in 5 patients and mild heart failure in the other 4. Renal digoxin clearance was also evaluated in 8 of these patients. Serum digoxin concentration was measured at control, 7 +/- 2 days after initiation of 120 mg/day of diltiazem and 11 +/- 5 days after increasing the dose of diltiazem to 240 mg/day. Serum digoxin concentration was 0.9 +/- 0.4 ng/ml at control, 0.8 +/- 0.4 ng/ml with 120 mg/day of diltiazem, and 0.8 +/- 0.3 ng/ml during therapy with 240 mg/day. The differences between these values were not significant. Renal digoxin clearance also did not show a significant change after diltiazem therapy (44 +/- 15 ml/min before diltiazem and 46 +/- 13 ml/min with 240 mg/day of diltiazem). This study shows no effect of diltiazem in doses of 120 to 240 mg/day on serum digoxin concentration or renal digoxin clearance in patients who are treated chronically for heart disease with digoxin. In this dose range, diltiazem has advantages over verapamil, which markedly elevates digoxin levels.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004110 Diltiazem A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions. Aldizem,CRD-401,Cardil,Cardizem,Dilacor,Dilacor XR,Dilren,Diltiazem Hydrochloride,Diltiazem Malate,Dilzem,Tiazac,CRD 401,CRD401
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
July 1984, Clinical pharmacology and therapeutics,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
October 1984, Clinical pharmacology and therapeutics,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
November 1990, Zhonghua nei ke za zhi,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
January 1985, Acta medica Scandinavica,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
December 1987, Journal of clinical pharmacology,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
December 1980, The Journal of pharmacology and experimental therapeutics,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
April 1979, Journal of clinical pharmacology,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
September 1986, The American journal of medicine,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
January 1982, European journal of clinical pharmacology,
U Elkayam, and K Parikh, and B Torkan, and L Weber, and J L Cohen, and S H Rahimtoola
November 1984, Presse medicale (Paris, France : 1983),
Copied contents to your clipboard!